Overexpression of P-glycoprotein, STAT3, phospho-STAT3 and KIT in spontaneous canine cutaneous mast cell tumours before and after prednisolone treatment

Veterinary Journal

Volumn 193, Issue 2, 2012, Pages 551-556

  Teng, Shr Ping ^a   Hsu, Wei Li ^a   Chiu, Cheng Yang ^a   Wong, Min Liang ^a   Chang, Shih Chieh ^a  

^a NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

Author keywords

Canine; Drug resistance; Glucocorticoid; Mast cell tumour; Neoadjuvant chemotherapy; STAT3; Tumour regression

Indexed keywords

GLYCOPROTEIN P; PREDNISOLONE; STAT3 PROTEIN; STEM CELL FACTOR RECEPTOR;

AGE DISTRIBUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY LABELING; ARTICLE; BODY WEIGHT; CANCER STAGING; CONTROLLED STUDY; DOWN REGULATION; DRUG RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MASTOCYTOMA; NONHUMAN; PROTEIN EXPRESSION; SEX DIFFERENTIATION; SKIN TUMOR; TREATMENT DURATION; TUMOR DIFFERENTIATION; TUMOR REGRESSION; UPREGULATION;

ANIMALS; DOG DISEASES; DOGS; FEMALE; GLUCOCORTICOIDS; IMMUNOHISTOCHEMISTRY; MALE; MASTOCYTOMA; P-GLYCOPROTEIN; PHOSPHORYLATION; PREDNISOLONE; PROTO-ONCOGENE PROTEINS C-KIT; STAT3 TRANSCRIPTION FACTOR;

CANIS FAMILIARIS;

EID: 84865862563     PISSN: 10900233     EISSN: 15322971     Source Type: Journal    
DOI: 10.1016/j.tvjl.2012.01.033     Document Type: Article

References (32)

1. Bourguignon L.Y., Peyrollier K., Xia W., Gilad E. Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. Journal of Biological Chemistry 2008, 283:17635-17651.
2. Bowman T., Garcia R., Turkson J., Jove R. STATs in oncogenesis. Oncogene 2000, 19:2474-2488.
3. Chaffin K., Thrall D.E. Results of radiation therapy in 19 dogs with cutaneous mast cell tumor and regional lymph node metastasis. Veterinary Radiology and Ultrasound 2002, 43:392-395.
4. Chaix A., Lopez S., Voisset E., Gros L., Dubreuil P., De Sepulveda P. Mechanisms of STAT protein activation by oncogenic KIT mutants in neoplastic mast cells. Journal of Biological Chemistry 2011, 286:5956-5966.
5. Dobson J., Cohen S., Gould S. Treatment of canine mast cell tumours with prednisolone and radiotherapy. Veterinary and Comparative Oncology 2004, 2:132-141.
6. Hahn K.A., King G.K., Carreras J.K. Efficacy of radiation therapy for incompletely resected grade-III mast cell tumors in dogs: 31 cases (1987-1998). Journal of the American Veterinary Medical Association 2004, 224:79-82.
7. Kaldrymidou H., Leontides L., Koutinas A.F., Saridomichelakis M.N., Karayannopoulou M. Prevalence, distribution and factors associated with the presence and the potential for malignancy of cutaneous neoplasms in 174 dogs admitted to a clinic in northern Greece. Journal of Veterinary Medicine. A. Physiology, Pathology and Clinical Medicine 2002, 49:87-91.
8. Kiupel M., Webster J.D., Kaneene J.B., Miller R., Yuzbasiyan-Gurkan V. The use of KIT and tryptase expression patterns as prognostic tools for canine cutaneous mast cell tumors. Veterinary Pathology 2004, 41:371-377.
9. Krasil'nikov M., Shatskaya V. Signal transducer and activator of transcription-3 and phosphatidylinositol-3 kinase as coordinate regulators of melanoma cell response to glucocorticoid hormones. Journal of Steroid Biochemistry and Molecular Biology 2002, 82:369-376.
10. Krishna R., Mayer L.D. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. European Journal of Pharmaceutical Sciences 2000, 11:265-283.
11. Lee J.J., Hughes C.S., Fine R.L., Page R.L. P-glycoprotein expression in canine lymphoma: A relevant, intermediate model of multidrug resistance. Cancer 1996, 77:1892-1898.
12. Levy D.E., Lee C.K. What does Stat3 do?. Journal of Clinical Investigation 2002, 109:1143-1148.
13. McCaw D.L., Miller M.A., Ogilvie G.K., Withrow S.J., Brewer W.G., Klein M.K., Bell F.W., Anderson S.K. Response of canine mast cell tumors to treatment with oral prednisone. Journal of Veterinary Internal Medicine 1994, 8:406-408.
14. Miyoshi N., Tojo E., Oishi A., Fujiki M., Misumi K., Sakamoto H., Kameyama K., Shimizu T., Yasuda N. Immunohistochemical detection of P-glycoprotein (PGP) and multidrug resistance-associated protein (MRP) in canine cutaneous mast cell tumors. Journal of Veterinary Medical Science 2002, 64:531-533.
15. Murphy S., Sparkes A.H., Blunden A.S., Brearley M.J., Smith K.C. Effects of stage and number of tumours on prognosis of dogs with cutaneous mast cell tumours. Veterinary Record 2006, 158:287-291.
16. Murphy S., Sparkes A.H., Smith K.C., Blunden A.S., Brearley M.J. Relationships between the histological grade of cutaneous mast cell tumours in dogs, their survival and the efficacy of surgical resection. Veterinary Record 2004, 154:743-746.
17. Nakaichi M., Takeshita Y., Okuda M., Nakamoto Y., Itamoto K., Une S., Sasaki N., Kadosawa T., Takahashi T., Taura Y. Expression of the MDR1 gene and P-glycoprotein in canine mast cell tumor cell lines. Journal of Veterinary Medical Science 2007, 69:111-115.
18. Okayama Y., Kawakami T. Development, migration, and survival of mast cells. Immunologic Research 2006, 34:97-115.
19. Pariante C.M. The role of multi-drug resistance p-glycoprotein in glucocorticoid function: Studies in animals and relevance in humans. European Journal of Pharmacology 2008, 583:263-271.
20. Patnaik A.K., Ehler W.J., MacEwen E.G. Canine cutaneous mast-cell tumor - Morphologic grading and survival-time in 83 dogs. Veterinary Pathology 1984, 21:469-474.
21. Sakai H., Toyota N., Ito F., Takahashi H., Hashimoto Y., Iizuka H. Glucocorticoids inhibit proliferation and adhesion of the IL-3-dependent mast cell line, MC/9, to NIH/3T3 fibroblasts, with an accompanying decrease in IL-3 receptor expression. Archives of Dermatological Research 1999, 291:224-231.
22. Seguin B., Besancon M.F., McCallan J.L., Dewe L.L., Tenwolde M.C., Wong E.K., Kent M.S. Recurrence rate, clinical outcome, and cellular proliferation indices as prognostic indicators after incomplete surgical excision of cutaneous grade II mast cell tumors: 28 dogs (1994-2002). Journal of Veterinary Internal Medicine 2006, 20:933-940.
23. Seguin B., Leibman N.F., Bregazzi V.S., Ogilvie G.K., Powers B.E., Dernell W.S., Fettman M.J., Withrow S.J. Clinical outcome of dogs with grade-II mast cell tumors treated with surgery alone: 55 cases (1996-1999). Journal of the American Veterinary Medical Association 2001, 218:1120-1123.
24. Sionov R.V., Spokoini R., Kfir-Erenfeld S., Cohen O., Yefenof E. Mechanisms regulating the susceptibility of hematopoietic malignancies to glucocorticoid-induced apoptosis. Advances in Cancer Research 2008, 101:127-248.
25. Speiran K., Bailey D.P., Fernando J., Macey M., Barnstein B., Kolawole M., Curley D., Watowich S.S., Murray P.J., Oskeritzian C., Ryan J.J. Endogenous suppression of mast cell development and survival by IL-4 and IL-10. Journal of Leukocyte Biology 2009, 85:826-836.
26. Stanclift R.M., Gilson S.D. Evaluation of neoadjuvant prednisone administration and surgical excision in treatment of cutaneous mast cell tumors in dogs. Journal of the American Veterinary Medical Association 2008, 232:53-62.
27. Thamm D.H., Turek M.M., Vail D.M. Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 cases. Journal of Veterinary Medical Science 2006, 8:581-587.
28. Thamm, D.H., Vail, D.M., 2007. Canine mast cell tumors. In: Withrow, S.J., Vail, D.M. (Eds.), Small Animal Clinical Oncology, Fourth Ed. St. Louis, Missouri, USA, pp. 402-421.
29. Turkson J. STAT proteins as novel targets for cancer drug discovery. Expert Opinion on Therapeutic Targets 2004, 8:409-422.
30. Webster J.D., Yuzbasiyan-Gurkan V., Miller R.A., Kaneene J.B., Kiupel M. Cellular proliferation in canine cutaneous mast cell tumors: Associations with c-KIT and its role in prognostication. Veterinary Pathology 2007, 44:298-308.
31. Weisse C., Shofer F.S., Sorenmo K. Recurrence rates and sites for grade II canine cutaneous mast cell tumors following complete surgical excision. Journal of the American Animal Hospital Association 2002, 38:71-73.
32. Wu C.C., Shyu R.Y., Chou J.M., Jao S.W., Chao P.C., Kang J.C., Wu S.T., Huang S.L., Jiang S.Y. RARRES1 expression is significantly related to tumour differentiation and staging in colorectal adenocarcinoma. European Journal of Cancer 2006, 42:557-565.